CAMS and LICR Sign Cooperative Framework Agreement


On December 8-12, 2016, CAMS President Xuetao Cao visited Oxford University. He met with Edward McDermott, Jr., who is the president of the Ludwig Institute for Cancer Research (LICR) as well as the chairman of the LICR Fund, to sign the CAMS-Ludwig Cancer Research Strategy Cooperative Framework Agreement. Prof. Bo Huang, Vice Director of the Institute of Basic Medical Sciences was also present.

During the signing of the agreement, President Cao and Vice President Robert L. Strausberg of LICR spoke about the current states of their respective institutions. President Cao stated that LICR has branches in a number of well-reputed universities and research organizations around the world, and it has made outstanding achievements in the areas of cancer treatment and prevention, whereas CAMS possesses unique merits in the realms of cancer research, pharmaceutical development, and clinical treatment. As a result, the two are expected to complement each other well. He expressed hopes that through collaboration, the two would drive the development of cancer treatment and prevention with greater force in China and throughout the world. Professor Xin Lu, the director of the LICR branch at Oxford and a fellow at the UK Academy of Medical Sciences, talked about the composition of the Oxford branch and specific research there. Lu graduated from the CAMS Cancer Institute & Hospital, studying under Academician Min Wu. After Lu’s talk, the two sides discussed cooperation affairs and had academic exchanges. 

LICR headquarters is in New York, and there are Ludwig branches at the New York-based Sloan-Kettering Cancer Center, Harvard, MIT, Stanford, John Hopkins, and the University of Chicago. Outside the US, there are Ludwig branches at the University of Lausanne in Switzerland, the Catholic University of Leuven in Belgium, the Karolinska Institutet and Uppsala University in Sweden, and Oxford in UK. LICR is a global nonprofit organization that provides financial assistance to top cancer researchers around the globe in the fields including tumor cell biology, tumor genomics, onco-immunology, cancer signaling, cancer stem cells, cancer therapy, and clinical cancer trials. Such efforts have led to amazing breakthroughs, such as the discovery of an epigenetic marker (5-hydroxymethylcytosine) in mammals by Kriaucionis and Heintz in 2009 and the prediction of the rise in immunotherapy by cancer immunity research pioneer Lloyd Old.


President Cao (front row, right) and President McDonald (front row, left) sign the framework agreement. Vice President, Professor Strausberg of LICR (second row, far right) and Professor Xin Lu, director of the LICR branch at Oxford and a fellow at the UK Academy of Medical Sciences (second row, fourth from left), were also present for the signing.


 (Institute of Basic Medical Sciences)